149 related articles for article (PubMed ID: 21321091)
1. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Stupp R; Tosoni A; Bromberg JEC; Hau P; Campone M; Gijtenbeek J; Frenay M; Breimer L; Wiesinger H; Allgeier A; van den Bent MJ; Bogdahn U; van der Graaf W; Yun HJ; Gorlia T; Lacombe D; Brandes AA
Ann Oncol; 2011 Sep; 22(9):2144-2149. PubMed ID: 21321091
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.
Freedman RA; Bullitt E; Sun L; Gelman R; Harris G; Ligibel JA; Krop IE; Partridge AH; Eisenberg E; Winer EP; Lin NU
Clin Breast Cancer; 2011 Dec; 11(6):376-83. PubMed ID: 21697017
[TBL] [Abstract][Full Text] [Related]
3. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.
Silvani A; Gaviani P; Fiumani A; Scaioli V; Lamperti E; Eoli M; Botturi A; Salmaggi A
J Neurooncol; 2009 Oct; 95(1):61-64. PubMed ID: 19381446
[TBL] [Abstract][Full Text] [Related]
4. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
5. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
Morrow PK; Divers S; Provencher L; Luoh SW; Petrella TM; Giurescu M; Schmelter T; Wang Y; Hortobagyi GN; Vahdat LT
Breast Cancer Res Treat; 2010 Oct; 123(3):837-42. PubMed ID: 20697802
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
Schmid P; Kiewe P; Possinger K; Korfel A; Lindemann S; Giurescu M; Reif S; Wiesinger H; Thiel E; Kühnhardt D
Ann Oncol; 2010 Mar; 21(3):633-639. PubMed ID: 19880436
[TBL] [Abstract][Full Text] [Related]
7. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U
Neuro Oncol; 2009 Apr; 11(2):158-66. PubMed ID: 18780814
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
Rustin G; Reed N; Jayson GC; Ledermann JA; Adams M; Perren T; Poole C; Lind M; Persic M; Essapen S; Gore M; Calvert H; Stredder C; Wagner A; Giurescu M; Kaye S
Ann Oncol; 2011 Nov; 22(11):2411-2416. PubMed ID: 21372124
[TBL] [Abstract][Full Text] [Related]
9. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
Arnold D; Voigt W; Kiewe P; Behrmann C; Lindemann S; Reif S; Wiesinger H; Giurescu M; Thiel E; Schmoll HJ
Br J Cancer; 2009 Oct; 101(8):1241-7. PubMed ID: 19773753
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
DeConti RC; Algazi AP; Andrews S; Urbas P; Born O; Stoeckigt D; Floren L; Hwang J; Weber J; Sondak VK; Daud AI
Br J Cancer; 2010 Nov; 103(10):1548-53. PubMed ID: 20924376
[TBL] [Abstract][Full Text] [Related]
11. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
12. First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.
Araki K; Kitagawa K; Mukai H; Mukohara T; Kodama K; Ando Y; Narabayashi M; Minami H; Mera K; Sasaki Y
Invest New Drugs; 2012 Dec; 30(6):2327-33. PubMed ID: 22139065
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.
McMeekin S; Patel R; Verschraegen C; Celano P; Burke J; Plaxe S; Ghatage P; Giurescu M; Stredder C; Wang Y; Schmelter T
Br J Cancer; 2012 Jan; 106(1):70-6. PubMed ID: 22108514
[TBL] [Abstract][Full Text] [Related]
16. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
van den Bent MJ; Grisold W; Frappaz D; Stupp R; Desir JP; Lesimple T; Dittrich C; de Jonge MJ; Brandes A; Frenay M; Carpentier AF; Chollet P; Oliveira J; Baron B; Lacombe D; Schuessler M; Fumoleau P; ;
Ann Oncol; 2003 Dec; 14(12):1732-4. PubMed ID: 14630677
[TBL] [Abstract][Full Text] [Related]
17. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
Heigener DF; von Pawel J; Eschbach C; Brune A; Schmittel A; Schmelter T; Reck M; Fischer JR
Lung Cancer; 2013 Jun; 80(3):319-25. PubMed ID: 23522488
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
[TBL] [Abstract][Full Text] [Related]
19. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
[TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
